Regeneron Pharmaceuticals Incorporated operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Regeneron Pharmaceuticals Incorporated with three other
companies in this sector in UNITED STATES :
sales of $6.68 billion
of which 53%
Vertex Pharmaceuticals Inc
of which 62%
was TRIKAFTA), and
Alexion Pharmaceuticals, Inc.
of which 67%
Sales were up sharply during the second
quarter of 2021 versus the previous year's second quarter.
During the second
quarter of 2021, sales at Regeneron Pharmaceuticals Incorporated totalled
an increase of 163.2%
from the $1.95 billion in sales at the company during the second quarter of 2020.
This was the biggest same quarter rise in sales at Regeneron Pharmaceuticals Incorporated in the previous 35 quarters.
During the first two
quarters of 2021, sales totalled $7.67 billion, which is
than through the first two quarters of 2020.
During the previous 34 quarters, sales at Regeneron Pharmaceuticals Incorporated have increased compared with the same quarter in the previous year.
Regeneron Pharmaceuticals Incorporated reported sales of $8.50 billion
December of 2020.
increase of 8.1%
versus 2019, when the company's sales were $7.86 billion.
Sales at Regeneron Pharmaceuticals Incorporated have increased during each of the previous five years
(and since 2015, sales have increased a total of 107%).
Sales of Libtayo saw an increase
that was more than double the company's growth rate: sales were up
54.1% in 2020, from
$175.70 million to $270.70 million.
Regeneron Pharmaceuticals Incorporated also saw significant increases in sales in
Other Revenues (up 34.7% to $557.00 million)
Not all segments of Regeneron Pharmaceuticals Incorporated experienced an increase in sales in 2020:
sales of Sanofi fell 16.8% to $1.19 billion.
Regeneron Pharmaceuticals Incorporated also experienced decreases in sales in
Bayer (down 0.2% to $1.19 billion)
Arcalyst (down 9.7% to $13.10 million)